Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT

Joseph F. Merola; Alice B.  Gottlieb; Jennifer Soung; Philip Hampton; Andreas Pinter; Melinda Gooderham; Akimichi Morita; Sarah Kavanagh; Nancy Cross; Susanne Wiegratz; Carle Paul

doi:10.25251/skin.8.supp.432

Joseph F. Merola

Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, Texas, USA

Alice B. Gottlieb

Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York, USA

Jennifer Soung

Southern California Dermatology, Santa Ana, California, USA

Philip Hampton

Department of Dermatology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Andreas Pinter

University Hospital Frankfurt, Frankfurt am Main, Germany

Melinda Gooderham

SKiN Centre for Dermatology, Probity Medical Research, Peterborough, Ontario, Canada; Queen’s University, Kingston, Ontario, Canada

Akimichi Morita

Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Sarah Kavanagh

UCB, Morrisville, North Carolina, USA

Nancy Cross

UCB, Morrisville, North Carolina, USA

Susanne Wiegratz

UCB, Monheim am Rhein, Germany

Carle Paul

Toulouse University and CHU, Toulouse, France

Keywords

psoriasis, bimekizumab, long-term efficacy, high-impact areas, scalp, nail, palmoplantar, quality of life, clinical trial

Abstract

References

1. Merola JF et al. Dermatol Ther 2018;31:e12589

2. Cashman MW et al. Clin Dermatol 2010;28:420–5

3. Adams R et al. Front Immunol 2020;11:1894

4. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747

5. Reich K et al. Lancet 2021;397:487–98, NCT03370133

6. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884

7. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992

8. Merola JF et al. Presented at EADV 2023; P2547

9. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790

10. European Medicines Agency. Bimekizumab Summary of Product Characteristics. 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-productinformation_en.pdf [Accessed September 2024].

PDF

Published

Nov 18, 2024

DOI https://doi.org/10.25251/skin.8.supp.432

How to Cite

[1]

Merola, J.F., Gottlieb, A.B., Soung, J., Hampton, P., Pinter, A., Gooderham, M., Morita, A., Kavanagh, S., Cross, N., Wiegratz, S. and Paul, C. 2024. Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s432. DOI:https://doi.org/10.25251/skin.8.supp.432.

Issue

Vol. 8 No. 6 (2024): November 2024 Issue

Section

Poster Presentations from FC24 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette, Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, Mark Lebwohl, David Adam, Javier Alonso-Llamazares, Chih-ho Hong, Steve Kempers, Leon Kircik, Wei Jing Loo, Daniel Stewart, Walter Nahm, Matthew Zirwas, Patrick Burnett, Robert Higham, Lynn Navale, David Berk, Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Javier Alonso-Llamazares, Melinda Gooderham, Jerry Bagel, John Browning, Zoe Draelos, Kimberly Grande, Adelaide Herbert, Wei Jing Loo, Chih-ho Hong, Mark Lebwohl, Walter Nahm, Kim Papp, David Pariser, Jennifer Soung, Linda Stein Gold, Irina Turchin, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Emma Guttman-Yassky, Stephan Weidinger, Eric Simpson, Melinda Gooderham, Alan Irvine, Lynda Spelman, Jonathan Silverberg, Hany Elmaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Chaoran Hu, Fan Emily Yang, Evangeline Pierce, Laia Bardolet, Diamant Thaci, Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Melissa Piliang, Jennifer Soung, Brett King, Jerry Shapiro, Lidia Rudnicka, Paul Farrant, Nina Magnolo, Bianca Piraccini, Xin Luo, Deborah Woodworth, Gregor Schaefer, Alexandre Lejeune, Robert Wolk, Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)